Priority Policy: The AI Conversation Heats Up

Artificial intelligence (AI) was a key topic at AdvaMed’s The MedTech Conference in Boston last month. More than 4,000 industry leaders and peers met to discuss trends, developments and challenges shaping global healthcare. Representatives from regulatory agencies in the United States and United Kingdom discussed upcoming policy developments for AI-enabled devices. 

Rick Abramson, director of the Digital Health Center of Excellence for the U.S. Food and Drug Administration (FDA), said to expect draft guidance on generative AI in the coming months. He described generative AI policy as a priority at the highest levels of the administration, including the secretary and the White House. 

Rick Abramson

The announcement follows an FDA discussion paper on regulatory approaches to generative AI-enabled medical devices. The comment period closed on October 19, 2026, and the agency received more than 500 submissions. The feedback will help inform the FDA’s approach to regulating this evolving technology. 

Abramson also discussed guidance related to risk assessment and evidence generation for generative AI-enabled devices, as well as efforts to finalize guidance on AI-enabled medical devices drafted in early 2025. The agency is also prioritizing guidance for AI-enabled devices used to address mental health conditions, following last year’s digital health advisory committee meetings on mental health chatbots.

Jessica Paulsen

Across the Atlantic, Jessica Paulsen, deputy director of AI and software for the Medicines and Healthcare Products Regulatory Agency (MHRA), talked about several policy developments underway at the U.K. regulator.

In early October, The MHRA moved to adopt 44 AI recommendations from an independent advisory group, the U.K. National Commission into the Regulation of AI in Healthcare. Some recommendations, such as monitoring the performance of generative AI-enabled devices after they reach the market, mirror issues raised in the FDA’s discussion paper. 

Paulsen emphasized the importance of monitoring AI performance in real-world settings, noting that assessments conducted at a single point in time may not fully reflect how a device performs over time. 

The MHRA also plans to draft guidance on a predetermined change control framework for postmarket medical device changes by the end of the year. Such a framework would help establish how manufacturers can manage changes to devices after they reach the market. The agency will consult early next year on how to qualify and classify AI-enabled devices, with the goal of sharing an implementation roadmap for the 44 recommendations by spring 2027. 

Read insights on AI policy from the AdvaMed MedTech Conference.

Learn more about ASG and what we do.